| Dr Nashita Molla, MD | |
|
1 Healthy Way, Oceanside, NY 11572-1551 | |
| (877) 768-8462 | |
| Not Available |
| Full Name | Dr Nashita Molla |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 6 Years |
| Location | 1 Healthy Way, Oceanside, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417449133 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 4301503778 (Michigan) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Covenant Visiting Nurse Association | Saginaw, MI | Home health agency |
| Covenant Medical Center | Saginaw, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Lakes Bay Health Centers | 2466369046 | 65 |
News Archive
How can damaged cardiac tissue following a heart attack best be treated with replacement muscle cells? A research team under the supervision of the University of Bonn is now presenting an innovative method on mice: Muscle replacement cells, which are to take over the function of the damaged tissue, are loaded with magnetic nanoparticles.
A team spanning Baylor College of Medicine, Rice University, Texas Children's Hospital and the Broad Institute of MIT and Harvard has developed a new way to sequence genomes, which can assemble the genome of an organism, entirely from scratch, dramatically cheaper and faster.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
Cambrex Corporation reports first quarter results for the period ended March 31, 2010.
› Verified 5 days ago
| Entity Name | Great Lakes Bay Health Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871684761 PECOS PAC ID: 2466369046 Enrollment ID: O20040126000171 |
News Archive
How can damaged cardiac tissue following a heart attack best be treated with replacement muscle cells? A research team under the supervision of the University of Bonn is now presenting an innovative method on mice: Muscle replacement cells, which are to take over the function of the damaged tissue, are loaded with magnetic nanoparticles.
A team spanning Baylor College of Medicine, Rice University, Texas Children's Hospital and the Broad Institute of MIT and Harvard has developed a new way to sequence genomes, which can assemble the genome of an organism, entirely from scratch, dramatically cheaper and faster.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
Cambrex Corporation reports first quarter results for the period ended March 31, 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nashita Molla, MD 21218 Hollis Ave, Queens Village, NY 11429-1823 Ph: () - | Dr Nashita Molla, MD 1 Healthy Way, Oceanside, NY 11572-1551 Ph: (877) 768-8462 |
News Archive
How can damaged cardiac tissue following a heart attack best be treated with replacement muscle cells? A research team under the supervision of the University of Bonn is now presenting an innovative method on mice: Muscle replacement cells, which are to take over the function of the damaged tissue, are loaded with magnetic nanoparticles.
A team spanning Baylor College of Medicine, Rice University, Texas Children's Hospital and the Broad Institute of MIT and Harvard has developed a new way to sequence genomes, which can assemble the genome of an organism, entirely from scratch, dramatically cheaper and faster.
The U.S. Patent and Trademark Office (USPTO) has held that all claims in Oculir's Patent No. 6,958,039 to be invalid as not patentable based on prior art from a patent disclosure by Yale researcher, Dr. Marc Abreu.
Cambrex Corporation reports first quarter results for the period ended March 31, 2010.
› Verified 5 days ago